昌吉市哪个妇科医院较好昌吉男科医院那就好,昌吉男性性功能障碍能不能治好,昌吉去医院上环需要多长时间,昌吉怎么看性功能障碍好,昌吉早早孕试纸,昌吉泌尿感染的治疗方法,昌吉取环要注意什么事项

JERUSALEM, July 25 (Xinhua) -- A new study carried out by a Tel Aviv University researcher indicates that the common backache may not only be caused by bad positions or aging, but also by your genes.Prof. Gregory Livshits of the Sackler Faculty of Medicine says that genes play a major role in back pain, especially in the lower back, and in spinal deterioration.In a decade-long project with 2,500 identical and non-identical twins, Livshits found that, in one Arab family, the same back problems appeared in all the members of the family, whether young or old.According to the study, non-identical twins were three times more likely to have back pain, while identical twins were six times more likely to have the same back problems.Livshits believes the discovery of the link between back pains and genes could lead to much better treatment.The research was developed in collaboration with a team of scientists at Kings College, London, led by Prof. Tim Spector and Dr. Fran Williams and was recently published in the journal " Annals of the Rheumatic Diseases."In order to better investigate the genetic causes for one of the world most common pains, Livshits and his colleagues hope to put together an international consortium of research groups.

SYDNEY, July 15 (Xinhua) -- The world's first drug to increase life expectancy of people with advanced melanoma has been approved for use in Australia, local media reported on Friday.The breakthrough drug Yervoy got approval from the Therapeutics Good Association (TGA) on Friday amid hopes it could add two years to the life of people with the most lethal form of skin cancer but for whom other treatments have failed, the Australian Associated Press (AAP) said.Clearance for the drug's use in Australia follows similar approvals by the U.S. health regulator in March.Yervoy works by attacking and destroying cancer cells.Patients are hooked up to an intravenous drip once every three weeks for a total of four doses.Professor Peter Hersey, consultant immunologist to the Melanoma Institute Australia, said no other drug had improved survival rates like Yervoy."Not all patients respond to it but those who do have a good chance of living longer than they would have otherwise," Hersey told AAP.While it may improve survival rates, Yervoy can produce side effects from diarrhea and vomiting to serious blood infections and kidney failure.The average survival time for people with advanced melanoma is just six months.A global study of 676 people with melanoma found that 45 percent of patients given Yervoy were still alive after one year, according to AAP.More than 20 percent lived at least two years, with a small number managing to survive for six years.A separate study, published in June, which showed similarly improved survival rates for patients with newly diagnosed advanced melanoma, has raised hopes that Yervoy could be made more widely available.Melanoma is the fourth most common cancer in Australia, with 10, 300 people diagnosed each year.

BEIJING, July 5 (Xinhuanet) -- A black iPhone 4 prototype has appeared for sale on eBay and the highest bidding hit one million U.S. dollars as of Monday, according to media reports.The listing is set to expire on July 11.The seller "jtmaxo" said, "I am a licensed cell phone repairman, this iPhone was bought from a person who really didn't know who he had."The seller later was frustrated to find that it was unable to be activated via iTunes.According to a check through Apple’s database, it is indeed listed as a prototype, and it has the tester code "DF1692" etched in the bottom right corner.Different from the iPhone 4 sold on markets, the handset lacks the + and - on the volume buttons, although the screen is fully functional.The price for the prototype will not remain as high as it is as the seller said that several "non-legitimate" bids have already been deleted.

BEIJING, Aug. 18 (Xinhua) -- A controlled trial has found that Chinese herbal medicine decoction maxingshigan-yinqiaosan has a similar efficacy to oseltamivir in reducing time to fever resolution in people suffering mild H1N1 influenza virus infections.Carried out by a group of Chinese researchers, headed by Prof. Wang Chen with Beijing Chao-Yang Hospital under the Capital Medical University, the study was published by the famous internal medicine journal Ann Intern Med on Tuesday.Participants of the trial were 410 young adults aged 15 to 59 years with laboratory-confirmed H1N1 influenza.The researchers concluded that both active intervention, alone and in combination, were effective in reducing time to fever resolution in young adults with H1N1 flu, and therefore suggest that maxingshigan-yinqiaosan may be an alternative to oseltamivir.

WELLINGTON, Sept. 27 (Xinhua) -- New Zealand and Japanese scientists are teaming up to develop healthier foods under two government-funded "functional foods" projects.One project, to be led by New Zealand's Massey University, will work with New Zealand food companies to create and develop a functional food with specific health enhancing effects for menopausal women, New Zealand Science and Innovation Minister Wayne Mapp announced Tuesday.The other project, to be led in New Zealand by Plant and Food Research, would use mass spectrometry to develop a "metabolic atlas" of the chemical composition of allium vegetables, such as onions and garlic, which the horticultural industry could use to develop new food products with health benefits.Mapp said the two research projects would be awarded a total of 1 million NZ dollars (782,000 U.S. dollars) in funding to strengthen collaborative research relationships between New Zealand and Japan, Mapp said."These research projects have strong commercial potential, including through the Japanese market, and so have the potential to benefit our economy," said Mapp."The government is committed to building and strengthening research relationships with other countries that will achieve world-class scientific results and lead to new innovative technologies."The two projects awarded funding under Ministry of Science and Innovation's Japan Science and Technology Agency (JST) funding round focus on functional foods. The ministry and Japan each fund half the cost of each research project awarded funding.